Most notably, we found that ARD LoF missense variants were enriched in the BRIDGES6 cohort (population-based OR = 6.75, 95% CI = 1.52 – 29.9, all sample cohorts OR = 7.07, 95% CI = 1.63 – 30.8) and LoF BRCT variants were also associated with increased ER− breast cancer risk in the CARRIERS45 cohort (OR = 3.15, 95% CI = 1.32 – 7.50) (Fig. 3d). Here, ADI1 is linked to breast cancer.